Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #25 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 435,863 | 146.5 | 13.7% | 11.0% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 246,660 | 83.9 | 15.3% | 62.7% | 0.32% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 162,454 | 78.2 | 12.2% | 34.6% | 0.79% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 115,910 | 33.3 | 17.3% | 17.2% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 108,736 | 35.4 | 11.2% | -11.0% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,969 | 122.5 | 17.1% | 127.1% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 103,406 | 47.4 | 11.7% | 2.6% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 102,916 | 154.7 | 10.9% | -0.9% | — | 62 | 33 | 71 |
| Acutaas Chemicals Limited (this stock) | 26,849 | 67.6 | 20.8% | 137.4% | 0.08% | 79 | 26 | 50 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 330 | 104 | 75 | ₹ |
| March 31, 2026 | 433 | 184 | 134 | ₹ |
| Dec. 31, 2025 | 393 | 145 | 106 | ₹ |
| Sept. 30, 2025 | 306 | 96 | 72 | ₹ |
| June 30, 2025 | 207 | 58 | 44 | ₹ |
| March 31, 2025 | 308 | 83 | 63 | ₹ |
| Dec. 31, 2024 | 275 | 63 | 45 | ₹ |
| Sept. 30, 2024 | 247 | 50 | 38 | ₹ |
| June 30, 2024 | 177 | 20 | 15 | ₹ |
| March 31, 2024 | 225 | 37 | 26 | ₹ |
| Dec. 31, 2023 | 166 | 24 | 18 | ₹ |
| Sept. 30, 2023 | 172 | -10 | -17 | ₹ |
| June 30, 2023 | 142 | 22 | 17 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 1,339 | 483 | 356 |
| March 31, 2025 | 1,007 | 216 | 160 |
| March 31, 2024 | 717 | 82 | 49 |
| March 31, 2023 | 617 | 112 | 83 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 292 | -266 | 4 | 328 | -36 |
| March 31, 2025 | 118 | -224 | 261 | 195 | -76 |
| March 31, 2024 | 125 | -365 | 239 | 280 | -155 |
| March 31, 2023 | 66 | -33 | -12 | 96 | -31 |
| March 31, 2022 | -9 | -124 | 140 | 0 | -9 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 1,984 | 1,711 | 1,613 | 26 | 0 | 881 | 231 | 216 | 633 | 231 |
| March 31, 2025 | 1,549 | 1,320 | 1,269 | 8 | 0 | 792 | 202 | 185 | 505 | 180 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
